Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma

Journal of Hepatology

Volumn 56, Issue 3, 2012, Pages 595-601

  Huynh, Hung ^a   Chow, Pierce Kah Hoe ^b   Tai, Wai Ming ^a   Choo, Su Pin ^a   Chung, Alexander Yaw Fui ^b   Ong, Hock Soo ^b   Soo, Khee Chee ^a   Ong, Richard ^a   Linnartz, Ronald ^c   Shi, Michael Ming ^c  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Angiogenesis; Dovitinib; Growth inhibition; HCC; Metastasis; Survival

Indexed keywords

AGAR; BEVACIZUMAB; CYCLIN B1; CYCLIN DEPENDENT KINASE 2; DOVITINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER MODEL; CANCER SURVIVAL; CELL MIGRATION; CONTROLLED STUDY; DEPHOSPHORYLATION; DOWN REGULATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG METASTASIS; M PHASE CELL CYCLE CHECKPOINT; MALE; METASTASIS INHIBITION; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETINOBLASTOMA; UPREGULATION; WESTERN BLOTTING; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL DIVISION; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; G2 PHASE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, SCID; QUINOLONES; SURVIVAL RATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84857357820     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.09.017     Document Type: Article

References (31)

1. A. Jemal, T. Murray, E. Ward, A. Samuels, R.C. Tiwari, and A. Ghafoor Cancer statistics, 2005 CA Cancer J Clin 55 2005 10 30
2. N. Nagasue, H. Kohno, Y.C. Chang, H. Taniura, A. Yamanoi, and M. Uchida Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years Ann Surg 217 1993 375 384
3. K. Takenaka, N. Kawahara, K. Yamamoto, K. Kajiyama, T. Maeda, and H. Itasaka Results of 280 liver resections for hepatocellular carcinoma Arch Surg 131 1996 71 76
4. E.M. Haugsten, A. Wiedlocha, S. Olsnes, and J. Wesche Roles of fibroblast growth factor receptors in carcinogenesis Mol Cancer Res 8 2010 1439 1452
5. X. Huang, C. Yu, C. Jin, M. Kobayashi, C.A. Bowles, and F. Wang Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis Cancer Res 66 2006 1481 1490
6. S. Ogasawara, H. Yano, A. Iemura, T. Hisaka, and M. Kojiro Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines Hepatology 24 1996 198 205
7. C. Gauglhofer, S. Sagmeister, W. Schrottmaier, C. Fischer, C. Rodgarkia-Dara, and T. Mohr Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis Hepatology 53 2011 854 864
8. N. Harimoto, K. Taguchi, K. Shirabe, E. Adachi, Y. Sakaguchi, and Y. Toh The significance of fibroblast growth factor receptor 2 expression in differentiation of hepatocellular carcinoma Oncology 78 2010 361 368
9. K. Nicholes, S. Guillet, E. Tomlinson, K. Hillan, B. Wright, and G.D. Frantz A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice Am J Pathol 160 2002 2295 2307
10. G. Bergers, S. Song, N. Meyer-Morse, E. Bergsland, and D. Hanahan Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J Clin Invest 111 2003 1287 1295
11. A. Ostman PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma Cytokine Growth Factor Rev 15 2004 275 286
12. R.T. Poon, C. Lau, W.C. Yu, S.T. Fan, and J. Wong High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study Oncol Rep 11 2004 1077 1084
13. M.R. Kano, Y. Morishita, C. Iwata, S. Iwasaka, T. Watabe, and Y. Ouchi VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling J Cell Sci 118 2005 3759 3768
14. H. Huynh, V.C. Ngo, S.P. Choo, D. Poon, H.N. Koong, and C.H. Thng Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma Curr Cancer Drug Targets 9 2009 738 747
15. H. Huynh, V.C. Ngo, J. Fargnoli, M. Ayers, K.C. Soo, and H.N. Koong Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma Clin Cancer Res 14 2008 6146 6153
16. S.H. Lee, D.M. Lopes, J. Vora, A. Harris, H. Ye, and L. Nordahl In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models Clin Cancer Res 11 2005 3633 3641
17. D.E. Lopes de Menezes, J. Peng, E.N. Garrett, S.G. Louie, S.H. Lee, and M. Wiesmann CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia Clin Cancer Res 11 2005 5281 5291
18. D. Sarker, R. Molife, T.R. Evans, M. Hardie, C. Marriott, and P. Butzberger-Zimmerli A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors Clin Cancer Res 14 2008 2075 2081
19. H. Huynh, V.C. Ngo, H.N. Koong, D. Poon, S.P. Choo, and H.C. Toh AZD6244 enhances the antitumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC) J Hepatol 52 2010 79 87
20. H. Huynh, K.C. Soo, P.K. Chow, L. Panasci, and E. Tran Xenografts of human hepatocellular carcinoma: a useful model for testing drugs Clin Cancer Res 12 2006 4306 4314
21. S.C. Heffelfinger, H.H. Hawkins, J. Barrish, L. Taylor, and G.J. Darlington SK HEP-1: a human cell line of endothelial origin In Vitro Cell Dev Biol 28A 1992 136 142
22. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, and J.S. Kim Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
23. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
24. H. Huynh, R.W. Ong, P.Y. Li, S.S. Lee, S. Yang, and L.W. Chong Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma Anticancer Agents Med Chem 11 2011 560 575
25. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 2008 592 603
26. O. Casanovas, D.J. Hicklin, G. Bergers, and D. Hanahan Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 2005 299 309
27. X. Xian, J. Hakansson, A. Stahlberg, P. Lindblom, C. Betsholtz, and H. Gerhardt Pericytes limit tumor cell metastasis J Clin Invest 116 2006 642 651
28. M. Paez-Ribes, E. Allen, J. Hudock, T. Takeda, H. Okuyama, and F. Vinals Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
29. J.M. Ebos, C.R. Lee, W. Cruz-Munoz, G.A. Bjarnason, J.G. Christensen, and R.S. Kerbel Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
30. S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, and H. Rong BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
31. L.Q. Chow, and S.G. Eckhardt Sunitinib: from rational design to clinical efficacy J Clin Oncol 25 2007 884 896